Adler, Julia M. http://orcid.org/0000-0001-8147-0351
Martin Vidal, Ricardo http://orcid.org/0000-0002-9670-5640
Langner, Christine http://orcid.org/0000-0001-7311-3477
Vladimirova, Daria
Abdelgawad, Azza
Kunecova, Daniela
Lin, Xiaoyuan http://orcid.org/0000-0002-3361-0126
Nouailles, Geraldine http://orcid.org/0000-0003-1973-3119
Voss, Anne
Kunder, Sandra http://orcid.org/0000-0002-5023-8397
Gruber, Achim D. http://orcid.org/0000-0002-4502-0393
Wu, Haibo http://orcid.org/0000-0002-5961-2947
Osterrieder, Nikolaus
Kunec, Dusan
Trimpert, Jakob http://orcid.org/0000-0003-1616-0810
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB-TR84 Z01b)
RocketVax AG c/o Swiss Rockets AG Rittergasse 3, 4051 Basel Switzerland
Article History
Received: 17 November 2023
Accepted: 17 January 2024
First Online: 2 February 2024
Competing interests
: Related to this work, Freie Universität Berlin has filed a patent application (PCT/EP2022/051215) for the use of sCPD9 and sCPD9-ΔFCS as vaccines. In this application, J.T., N.O., and D.K. are named as inventors of sCPD9. The patent application does not preclude the use of sCPD9 for scientific purposes. Freie Universität Berlin is collaborating with RocketVax Inc. for further development of sCPD9-ΔFCS as a vaccine and receives funding for research. The remaining authors declare no competing interests.